June 23, 2021
1 min watch
Save
VIDEO: ‘Exciting’ data update from CodeBreak100 trial
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Pasi A. Jänne, MD, PhD, discussed updated data from the phase 2 CodeBreak100 trial presented at the virtual ASCO Annual Meeting.
“[This is] an exciting area in the lung cancer space because KRAS G12C mutations are so common,” Jänne, director of the Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science and Chen-Huang Center for EGFR Mutant Lung Cancers, and senior physician and professor of medicine at Harvard Medical School, said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview; Skoulidis F, et al. Abstract 9003. Scheduled for presentation at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.
Disclosures:
Janne reports receiving stock and other ownership interests from Gatekeeper Pharmaceuticals and Loxo Oncology; serving in a consulting or advisory role for Araxes Pharma, AstraZeneca, Bayer, Biocartis, Biocartis, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, Eisai, Ignyta, Lilly, LOXO, Merrimack, Mirati Therapeutics, Novartis, Nuvalent Inc., Pfizer, Roche/Genentech, Sanofi, SFJ Pharmaceuticals Group, Silicon Therapeutics, Takeda and Voronoi; and receiving research funding from Astellas Pharma, AstraZeneca, Boehringer Ingelhei, Daiichi Sankyo, Lilly, Puma Biotechnology, Revolution Medicines and Takeda.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.